- Atorvastatin that non-preparation method
-
The invention relates to a preparation method of avanafil and a new compound provided in a preparation process. According to the method, 5-uracil carboxylic acid or an ester thereof is taken as the raw material, and the avanafil meeting the clinical requirements can be synthesized at a relatively cost; besides, the preparation method is simple and convenient to operate, mild in reaction conditions, high in yield, low in cost, environmentally friendly and suitable for industrial large-scale production of the avanafil.
- -
-
Paragraph 0106; 0108
(2017/07/01)
-
- 5 OXO-5,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS CAMKII KINASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES
-
The present invention relates to 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives, to their preparation and to their therapeutic use.
- -
-
Page/Page column 16
(2012/11/08)
-
- Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors
-
A new series of pyrazolo[3,4-d]pyrimidine-3,6-diamines was designed and synthesized as potent and selective inhibitors of the nonreceptor tyrosine kinase, ACK1. These compounds arose from efforts to rigidify an earlier series of N-aryl pyrimidine-5-carboxamides. The synthesis and structure-activity relationships of this new series of inhibitors are reported. The most promising compounds were also profiled for their pharmacokinetic properties.
- Kopecky, David J.,Hao, Xiaolin,Chen, Yi,Fu, Jiasheng,Jiao, XianYun,Jaen, Juan C.,Cardozo, Mario G.,Liu, Jinsong,Wang, Zhulun,Walker, Nigel P.C.,Wesche, Holger,Li, Shyun,Farrelly, Ellyn,Xiao, Shou-Hua,Kayser, Frank
-
scheme or table
p. 6352 - 6356
(2009/09/06)
-
- COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS
-
The present invention relates to the use of a 2-cyanopyrimidine compound of the formula (I), wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and , where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.
- -
-
Page/Page column 72
(2008/06/13)
-